Clinical Trial

Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment

Study acronym: SPARC
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This study is examining the effects of standard of care cancer treatment as well as a medication called Sildenafil, on the cancer associated fatigue, cognition and the gut microbiome.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-01-23; most recent amendment 2026-05-08.
Status change: Recruiting → Not Yet Recruiting 2025-11-17
Trial Details
NCT Number NCT06800092
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions Cancer
Enrollment 30 participants
Start Date 2027-06-15
Primary Completion 2030-06-01 (estimated)
Study Completion 2030-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-11